| 000 | 01868 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515194724.0 | ||
| 264 | 0 | _c20100303 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a0300-0605 | ||
| 024 | 7 |
_a10.1177/147323000903700515 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, M | |
| 245 | 0 | 0 |
_aInhibition of the replication of hepatitis B virus in vitro by oxymatrine. _h[electronic resource] |
| 260 |
_bThe Journal of international medical research _c |
||
| 300 |
_a1411-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAlkaloids _xpharmacology |
| 650 | 0 | 4 |
_aAntiviral Agents _xpharmacology |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 |
_aDNA, Viral _xgenetics |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 |
_aHepatitis B _xdrug therapy |
| 650 | 0 | 4 |
_aHepatitis B Surface Antigens _xmetabolism |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xmetabolism |
| 650 | 0 | 4 |
_aHepatitis B virus _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Situ Nick-End Labeling |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xpharmacology |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aQuinolizines _xpharmacology |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aReverse Transcriptase Polymerase Chain Reaction |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aVirus Replication _xdrug effects |
| 700 | 1 | _aYang, L Y | |
| 700 | 1 | _aLi, W Y | |
| 700 | 1 | _aPeng, Y P | |
| 700 | 1 | _aZheng, Jia-Kun | |
| 773 | 0 |
_tThe Journal of international medical research _gvol. 37 _gno. 5 _gp. 1411-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/147323000903700515 _zAvailable from publisher's website |
| 999 |
_c19315653 _d19315653 |
||